Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Senter

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Nature Biotechnology|June 16, 2015
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic indexRobert P Lyon, Tim D Bovee, Svetlana O Doronina, et al.
Molecular Cancer Therapeutics|June 6, 2018
Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR<sup>+</sup> and Heterogeneous Tumor ModelsPatrick J Burke, Joseph Z Hamilton, Thomas A Pires, et al.
Journal of Medicinal Chemistry|March 4, 2005
Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugatesScott C Jeffrey, Michael Y Torgov, Jamie B Andreyka, et al.
Bioconjugate Chemistry|September 22, 2005
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfidesMichael M C Sun, Kevin S Beam, Charles G Cerveny, et al.
Nature Biotechnology|September 8, 2014
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugatesRobert P Lyon, Jocelyn R Setter, Tim D Bovee, et al.
Journal of Medicinal Chemistry|May 31, 2002
Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activityAngeles Dios, Robert A Mitchell, Bayan Aljabari, et al.
Bioconjugate Chemistry|May 18, 2006
Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugatesScott C Jeffrey, Jamie B Andreyka, Starr X Bernhardt, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Auristatin S: An Auristatin Payload with Improved Tolerability and Modified Bystander ActivityPhilip N Moquist, Nicole M-L Eng-Duncan, Tim D Bovee, et al.
Bioconjugate Chemistry|January 19, 2006
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicitySvetlana O Doronina, Brian A Mendelsohn, Tim D Bovee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugatesChe-Leung Law, Charles G Cerveny, Kristine A Gordon, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Nature Biotechnology|June 16, 2015
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic indexRobert P Lyon, Tim D Bovee, Svetlana O Doronina, et al.
Molecular Cancer Therapeutics|June 6, 2018
Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR<sup>+</sup> and Heterogeneous Tumor ModelsPatrick J Burke, Joseph Z Hamilton, Thomas A Pires, et al.
Journal of Medicinal Chemistry|March 4, 2005
Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugatesScott C Jeffrey, Michael Y Torgov, Jamie B Andreyka, et al.
Bioconjugate Chemistry|September 22, 2005
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfidesMichael M C Sun, Kevin S Beam, Charles G Cerveny, et al.
Nature Biotechnology|September 8, 2014
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugatesRobert P Lyon, Jocelyn R Setter, Tim D Bovee, et al.
Journal of Medicinal Chemistry|May 31, 2002
Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activityAngeles Dios, Robert A Mitchell, Bayan Aljabari, et al.
Bioconjugate Chemistry|May 18, 2006
Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugatesScott C Jeffrey, Jamie B Andreyka, Starr X Bernhardt, et al.
ACS Medicinal Chemistry Letters|July 16, 2025
Auristatin S: An Auristatin Payload with Improved Tolerability and Modified Bystander ActivityPhilip N Moquist, Nicole M-L Eng-Duncan, Tim D Bovee, et al.
Bioconjugate Chemistry|January 19, 2006
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicitySvetlana O Doronina, Brian A Mendelsohn, Tim D Bovee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugatesChe-Leung Law, Charles G Cerveny, Kristine A Gordon, et al.
Pageof 9